Arnon P. Kater — Amsterdam UMC research portal

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018

Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia - touchONCOLOGY

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

G.J.C. ZWEZERIJNEN, Nuclear medicine physician, Master of Science, Amsterdam University Medical Center, Amsterdam, VUmc, Department of Nuclear Medicine and PET Research

Arnon KATER, Doctor of Medicine, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL - Haselager - 2023 - Molecular Oncology - Wiley Online Library

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

PDF) Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities